Abstract:
The present invention discloses a method for implementing multicast services, which includes: preset a mapping relation between a multicast user address and a multicast group address; acquire a request packet sent by the multicast user who requests to join in the multicast group; determine whether the multicast group address in request packet is the same as that corresponding to the multicast user in the established mapping relation according to the multicast user address and multicast group address carried in the request packet. If yes, allow the multicast user to join in the multicast group. Otherwise, prohibit the multicast user from joining in the multicast group. The present invention can open the preset multicast resources to the preset multicast user with speed and pertinence. At the same time, it limits the maximum number of multicast groups that each multicast user is allowed to join in, which can effectively control multicast service bandwidth and further protect the network equipment.
Abstract:
The present invention provides an anti-tumor or anti-angiogenesis medicament, the combination or kit containing the medicament, and the method for producing the same. The anti-tumor or anti-angiogenesis medicament contains a conjugate comprising a modifying agent and the angiostatin or its fragments, wherein the conjugate exhibits prolonged in vivo half-life as compared to an unmodified angiostatin or its fragments. The modifying agent is selected from the group consisting of macromolecular polymers, protein molecules or fragments thereof, peptides, small molecules, or chemical substances of any other forms.
Abstract:
Compositions and methods for identifying nucleotide fragments that contain an open reading frame are provided. Compositions comprise a nucleotide sequence that encodes, in each of the three possible reading frames, an ATG start codon and a histidine tag, and vectors comprising such a nucleotide sequence. The vectors may be provided with cloning sites for insertion of nucleotide sequences of interest 5′ or 3′ to the 3-frame His-tag DNA sequence. Vectors also are provided with cloning sites for inserting nucleotide sequences of interest 3′ of the ATG start codon and 5′ of the 3-frame His-tag DNA sequence.
Abstract:
The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.
Abstract:
The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents.
Abstract:
The present invention relates to the diagnosis and treatment of cancer, and specifically to a method of diagnosing the presence or metastasis of cancer by detecting plasma Hsp90α having the amino acid sequence of SEQ ID No. 1 as a tumor marker. In addition, the present invention also relates to a method for the treatment of cancer and metastasis.
Abstract translation:本发明涉及癌症的诊断和治疗,具体涉及通过检测具有SEQ ID No.1的氨基酸序列的血浆Hsp90α作为肿瘤标记物来诊断癌症存在或转移的方法。 此外,本发明还涉及治疗癌症和转移的方法。
Abstract:
The present invention relates to a method of identifying cancer subjects, in particular human patients, who are suitable for anti-lymphangiogenesis therapy to prevent tumor growth and tumor metastasis. The present invention also relates to a new approach, which uses nucleolin as a bait to search and screen for lymphangiogenesis inhibitors or cancer suppressors, which function in a manner that is analogous to endostatin. The invention is based upon the discovery that nucleolin is specifically expressed on lymphangiogenic vessels and functions as a specific receptor for endostatin, and thus is involved in the signal transduction pathway of endostatin as an anti-lymphangiogenesis inhibitor. The present invention also discloses that cell surface nucleolin on lymphatic endothelial cells is a biomarker for lymphangiogenic vessels, which could be used for the prediction of tumor metastasis.
Abstract:
An approach is provided for selecting a network server. An apparatus comprising at least one processor, and at least one memory including computer program code, the at least one memory and the computer program code configured to, with the at least one processor, cause, at least in part, the apparatus to load from one or more network servers configuration information of one or more network servers used by a service provider network. The apparatus is also caused to select a network server in the service provider network based at least in part on at least one of network server latency and the network server load. The apparatus is further caused to set the network server as default network server used for at least one of current and future session on one or more user equipment.
Abstract:
An approach is provided for building a scalable service platform by initiating transmission of encrypted data from a public network cache. An access control server platform determines a first authorization key for a user and a second authorization key for a resource, and then encrypts the resource with the second authorization key, and encrypts the second authorization key with the first authorization key. The access control server platform initiates distribution of the encrypted second authorization key with the encrypted resource over a network. The access control server platform further initiates caching the encrypted second authorization key with the encrypted resource that meets a predefined threshold value (e.g., a data size, an access frequency, a modification frequency, or an auditing requirement) in a cache in the network, and initiates transmission of the cached and encrypted second authorization key with the cached and encrypted resource from the cache to at least one authorized entity.
Abstract:
The present invention discloses an anti-tumor conjugate and pharmaceutical composition or kits comprising the conjugate, as well as a method of producing the anti-tumor conjugate. The anti-tumor conjugate of the present invention is metabolically stable in vivo, and is ultimately available for the treatment of tumors and production of anti-tumor medicaments.